Advanced Renal Cell Carcinoma: Comparing Frontline IO/TKI Combination Regimens

Dr. Monty Pal compares the available immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combination regimens for the first-line treatment of advanced renal cell carcinoma (RCC) and explains the clinical rationale behind his preferred treatment approach. He reviews the efficacy and long-term outcomes associated with several pivotal clinical trials, discussing progression-free survival, overall survival, response rates, and complete response rates while also considering the practical challenges encountered in routine clinical practice. Dr. Pal highlights how treatment tolerability, dose intensity, and quality-of-life considerations influence regimen selection, noting that differences between clinical trial protocols and real-world dosing can affect treatment outcomes. Drawing upon both published evidence and his own clinical experience, he explains why a nivolumab and cabozantinib combination has become his preferred immunotherapy and tyrosine kinase inhibitor regimen for many patients requiring an IO/TKI approach. The discussion underscores the importance of balancing efficacy, tolerability, and patient-centered considerations when selecting frontline therapy for advanced renal cell carcinoma.